No-carrier-added i-mibg: an initial clinical study in patients with phaeochromocytoma

Nuclear Medicine Communications

Volumn 21, Issue 5, 2000, Pages 437-440

  Owens, J ^a   Bolster, A A ^a   Prosser, J E ^a   Cunningham, S ^a   Mairs, R J ^b   Neilly, J B ^b   Reed, N S ^b   Hilditch, T E ^b  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADRENAL TUMOR; ADULT; ARTICLE; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PHEOCHROMOCYTOMA; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ADULT; CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034184715     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200005000-00005     Document Type: Article

References (10)

1. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology - role in the management of neural crest tumors. Eur J Nucl Med 1994; 21: 561-581.
2. Mangner TJ, Wu JL, Wieland DM. Solid-phase exchange radioiodination of aryl iodides - facilitation by ammonium-sulfate. J Organic Chem 1982; 47: 1484-1488.
3. Fredrikson M, Hursti TJ, Steineck G et al. Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. Br J Cancer 1994; 70: 642-645.
4. Mairs RJ, Cunningham SH, Russell J et al.No-carrier-added iodine-131-MIBG - evaluation of a therapeutic preparation. J Nucl Med 1995; 36: 1088-1095.
5. Mairs RJ, Russell J, Cunningham S et al. Enhanced tumor uptake and in-vitro radiotoxicity of no-carrier-added [I-131] metaiodobenzylguanidine - implications for the targeted radiotherapy of neuroblastoma. Eur J Cancer 1995; 31A: 576-581.
6. Vaidyanathan G, Zalutsky MR. No-carrier-added synthesis of meta-[I-131]iodobenzylguanidine. Appl Radiat Isotopes 1993; 44: 621-628.
7. Solanki KK, Bomanji J, Moyes J et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabeled metaiodobenzylguanidine. Nucl Med Commun 1992; 13: 513-521.
8. Bolster AA, Hilditch TE. Dosimetric considerations in I-131 MIBG therapy for neuroblastoma in children. Br J Radiol 1995; 68: 1263.
9. Mairs RJ, Zalutsky MR. New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment. Br J Cancer 1995; 72: 250.
10. Rutgers M, Buitenhuis C, Tytgart L et al. Metabolic targeting with [131I] meta-iodobenzylguanidine (MIBG) in cell cultures and xenografts of human neuroblastoma and rat pheochromocytoma, and in human platelets. Clin Chem Enzymol Commun 1993; 6: 27-37.